The Human Hookworm Vaccine.
The Human Hookworm Vaccine.
复制标题
DOI：
10.1016/j.vaccine.2012.11.034
复制
发表时间：
2013-04-18
期刊：
影响因子：
5.5
通讯作者：
Russell, Philip K.
中科院分区：
文献类型：
--
作者：
Hotez, Peter J.;Diemert, David;Bacon, Kristina M.;Beaumier, Coreen;Bethony, Jeffrey M.;Bottazzi, Maria Elena;Brooker, Simon;Couto, Artur Roberto;Freire, Marcos da Silva;Homma, Akira;Lee, Bruce Y.;Loukas, Alex;Loblack, Marva;Morel, Carlos Medicis;Oliveira, Rodrigo Correa;Russell, Philip K.
人体钩虫感染是导致缺铁性贫血的主要原因。发展中国家估计有7亿人受到影响。萨宾疫苗研究所PDP正在与FIOCRUZ合作开发疫苗。该疫苗包含明矾上的两种重组蛋白抗原和TLR 4激动剂。该伙伴关系的计划是，该疫苗将在2020年获得许可。钩虫感染是世界上最常见的被忽视的热带疾病之一，也是中低收入国家缺铁性贫血的主要原因。萨宾疫苗研究所目前正在开发一种人类钩虫疫苗，并正在进行第一阶段临床试验。候选疫苗由称为Na-GST-1和Na-APR-1的两种重组抗原组成，每种抗原都是钩虫成功利用宿主血液作为能量来源所需的重要寄生虫酶。重组蛋白在Alhydrogel®上配制，并与合成的Toll样受体4激动剂组合进行测试。疫苗的目的是诱导抗酶抗体，减少宿主失血和附着在肠道上的钩虫数量。计划将生产技术转让给Oswaldo Cruz基金会（FIOCRUZ）/Bio-Manguinhos（一家巴西公共部门发展中国家疫苗生产商），并制定了一项临床开发计划，可能导致该疫苗在巴西注册。这种疫苗还需要在钩虫感染高度流行的非洲和亚洲最贫穷地区推广。最终，该疫苗可能成为实现钩虫控制和消除的重要工具，这是2012年《关于被忽视的热带病的伦敦宣言》的一个关键目标。
► Human hookworm infection is a leading cause of iron deficiency anemia. ► An estimated 700 million people in developing countries are affected. ► The Sabin Vaccine Institute PDP is developing the vaccine in collaboration with FIOCRUZ. ► The vaccine comprises two recombinant protein antigens on alum and a TLR4 agonist. ► The partnership's plan is that the vaccine will be licensed by 2020. Hookworm infection is one of the world's most common neglected tropical diseases and a leading cause of iron deficiency anemia in low- and middle-income countries. A Human Hookworm Vaccine is currently being developed by the Sabin Vaccine Institute and is in phase 1 clinical testing. The candidate vaccine is comprised of two recombinant antigens known as Na-GST-1 and Na-APR-1, each of which is an important parasite enzyme required for hookworms to successfully utilize host blood as a source of energy. The recombinant proteins are formulated on Alhydrogel® and are being tested in combination with a synthetic Toll-like receptor 4 agonist. The aim of the vaccine is to induce anti-enzyme antibodies that will reduce both host blood loss and the number of hookworms attached to the gut. Transfer of the manufacturing technology to the Oswaldo Cruz Foundation (FIOCRUZ)/Bio-Manguinhos (a Brazilian public sector developing country vaccine manufacturer) is planned, with a clinical development plan that could lead to registration of the vaccine in Brazil. The vaccine would also need to be introduced in the poorest regions of Africa and Asia, where hookworm infection is highly endemic. Ultimately, the vaccine could become an essential tool for achieving hookworm control and elimination, a key target in the 2012 London Declaration on Neglected Tropical Diseases.
登录
查看更多内容
DOI：
10.1111/j.1365-2222.2009.03433.x
发表时间：
2010-02
期刊：
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
影响因子：
--
作者：
Feary JR;Venn AJ;Mortimer K;Brown AP;Hooi D;Falcone FH;Pritchard DI;Britton JR
通讯作者：
Britton JR
影响因子：
5.5
作者：
Hotez, Peter
通讯作者：
Hotez, Peter
影响因子：
15.8
作者：
Hotez PJ;Molyneux DH;Fenwick A;Ottesen E;Ehrlich Sachs S;Sachs JD
通讯作者：
Sachs JD
DOI：
10.1016/0035-9203(95)90101-9
发表时间：
1995-09-01
影响因子：
2.2
作者：
ALBONICO, M;SMITH, PG;SAVIOLI, L
通讯作者：
SAVIOLI, L
影响因子：
5.5
作者：
Lee, Bruce Y.;Bacon, Kristina M.;Smith, Kenneth J.
通讯作者：
Smith, Kenneth J.